Literature DB >> 8898164

Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival.

L P Pertschuk1, S Masood, J Simone, J G Feldman, R G Fruchter, C A Axiotis, G L Greene.   

Abstract

UNLABELLED: Only a few parameters such as tumor grade and stage are of value in prognosticating disease course in endometrial carcinoma. Biochemical steroid hormone receptor assays could also be useful but are difficult to perform and interpret. Immunocytochemical assay (ICA) might be the method of choice for detecting endometrial receptors.
METHODS: Frozen tissue from 78 cases of endometrial adenocarcinoma was examined for the presence of estrogen (ER) and progesterone receptors (PgR) with specific monoclonal anti-receptor antibodies and the peroxidase-antiperoxidase method. In over 60 cases, frozen tissue was also assayed for ER and PgR by biochemical means.
RESULTS: Fifty-five (71%) of the endometrial carcinomas were ERICA-positive and 55 (71%) PgRICA-positive. Although both ERICA and PgRICA correlated significantly with biochemical ER and PgR only ERICA was predictive of survival. A woman with a negative ERICA was 4 times more likely to die of her disease than if she were ERICA-positive (P = 0.009; mean follow-up, 37.5 months). Three cases ERICA-positive and PgRICA-negative survived while 3 others ERICA-negative and PgRICA-positive died.
CONCLUSION: ERICA, a technique easy to perform and interpret at the community hospital level, appears to provide prognostic information independent of tumor stage and grade. Such information might be of value in planning postoperative therapies for women with endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898164     DOI: 10.1006/gyno.1996.0273

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

2.  Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer.

Authors:  Yuan Yuan; Ning Shen; Shu-Yan Yang; Ling Zhao; Yong-Mei Guan
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

3.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

4.  Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.

Authors:  Tetsuya Tsujikawa; Yoshio Yoshida; Yasushi Kiyono; Tetsuji Kurokawa; Takashi Kudo; Yasuhisa Fujibayashi; Fumikazu Kotsuji; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

5.  Endometrioid adenocarcinoma arising in adenomyosis: elucidation by periodic magnetic resonance imaging evaluations.

Authors:  Kenichi Motohara; Hironori Tashiro; Hideyuki Ohtake; Fumitaka Saito; Takashi Ohba; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

6.  Insulin-like growth factors in endometrioid adenocarcinoma: correlation with clinico-pathological features and estrogen receptor expression.

Authors:  Yuan-Jiao Liang; Qun Hao; Hui-Ming Zhang; Yuan-Zhe Wu; Jian-Dong Wang
Journal:  BMC Cancer       Date:  2012-06-21       Impact factor: 4.430

Review 7.  Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.

Authors:  Yanli Zhang; Dong Zhao; Changguo Gong; Fengmei Zhang; Jing He; Wei Zhang; Yulan Zhao; Jing Sun
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

8.  Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.

Authors:  Hila Kreizman-Shefer; Jana Pricop; Shlomit Goldman; Irit Elmalah; Eliezer Shalev
Journal:  Diagn Pathol       Date:  2014-03-31       Impact factor: 2.644

9.  Involvements of Estrogen Receptor, Proliferating Cell Nuclear Antigen and p53 in Endometrial Adenocarcinoma Development in Donryu Rats.

Authors:  Midori Yoshida; Shin-Ichi Katsuda; Akihiko Maekawa
Journal:  J Toxicol Pathol       Date:  2012-12-20       Impact factor: 1.628

10.  Multiple brain metastases in a patient with uterine papillary serous adenocarcinoma: Treatment options for this rarely seen metastatic brain tumor.

Authors:  Salih Gulsen; Aysen Terzi
Journal:  Surg Neurol Int       Date:  2013-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.